Welcome to our dedicated page for Barrick Mining news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining stock.
Barrick Mining Corporation reports developments tied to its global gold and copper mining, exploration and development portfolio. Company news commonly covers operating and financial results, mine and project updates, technical and governance matters, and capital allocation actions for common shares that trade on the NYSE under B and on the TSX under ABX.
Recurring updates include quarterly results releases, dividend declarations, share repurchase authorizations, annual meeting materials and changes in executive or board oversight. Barrick also reports on its gold assets in North America and other mining jurisdictions, including disclosures connected to major mines, development projects, reserves, production, costs, cash flow and responsible mining obligations.
TrustPoint and Hexagon | NovAtel (TSX:HEXA) announced a successful demonstration of TrustPoint’s C-band satellite navigation signals operating on an enhanced NovAtel receiver in the presence of GNSS interference, under a Naval Air Systems Command SBIR Phase II effort led by NAWCAD.
According to TrustPoint, the test shows its C-band service can be acquired, tracked and used for precise positioning in GPS-degraded or denied environments, advancing commercialization of GNSS-independent, resilient PNT. The work builds on earlier milestones, including the first live-sky C-band GNSS signal in 2025 and three commercial free-flying GNSS satellites.
BioArctic (NASDAQ Stockholm: BIOA B) reports that partner Eisai has launched lecanemab-irmb subcutaneous injection, branded Leqembi Iqlik, in the US for initiation therapy in early Alzheimer's disease, following FDA approval on July 13. The at-home autoinjector provides a first-of-its-kind anti-amyloid option for both initiation and maintenance treatment, offering an alternative to intravenous infusions. The approved US initiation regimen is 500 mg once weekly, delivered as two 250 mg injections of about 15 seconds each. MRI monitoring for ARIA remains required. Leqembi, originating from BioArctic and Eisai’s alliance, is now approved in 53 countries, with BioArctic entitled to sales milestones and global royalties while bearing no development costs for Alzheimer's indications.
BioArctic (Nasdaq Stockholm: BIOA B) and Mesenkia Therapeutics have signed a research collaboration agreement to develop a novel antibody-based approach for glioblastoma, a highly aggressive brain cancer where delivery of large molecules to the brain is difficult.
The project will combine BioArctic's BrainTransporter™ technology with a Mesenkia KITAIbodies®-derived antibody targeting HVEM on glioblastoma tumor and tumor stem cells. BioArctic will generate the drug candidate, after which both parties plan preclinical studies to validate the concept and then decide on further steps. The collaboration is described as expanding BioArctic's BrainTransporter pipeline into oncology and leveraging Mesenkia's glioblastoma-focused antibody expertise.
BioArctic (Nasdaq Stockholm: BIOA B) will publish its second quarter report for April–June 2026 on August 26, 2026 at 8:00 a.m. CEST. A live English-language webcast and teleconference with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 9:30 a.m. CEST, including a Q&A session.
Barrick Mining (NYSE:B) has appointed Sebastiaan Bock as Chief Executive Officer, Rest of World, effective immediately. Bock will oversee Barrick’s gold and copper operations and projects outside North America and report to President and CEO Mark Hill.
Barrick’s Rest of World portfolio spans Africa, the Middle East, Latin America and Asia Pacific, producing more than two million gold equivalent ounces a year and expected, according to Barrick, to grow by over 20% in the next three years. Bock previously served as CFO and then COO for Africa and the Middle East, where the region met or exceeded guidance annually and delivered growth, including the Lumwana expansion, record throughput at Kibali, and reserve growth at Loulo-Gounkoto and Bulyanhulu.
Barrick Mining (NYSE:B) and Newmont have amended their Nevada Gold Mines (NGM) joint venture agreement to contribute previously excluded properties, including Barrick’s Fourmile and Newmont’s Fiberline and Mike developments, into NGM. The agreement concludes all outstanding NGM-related disputes between the companies.
According to Barrick, Newmont will provide $1.95 billion in consideration to Barrick to reflect the value of the contributed properties. Newmont has also consented to Barrick’s proposed IPO of its North American gold assets. The modernized JV includes enhanced governance provisions aimed at maximizing long-term value and performance.
Barrick Mining (NYSE:B) reported strong Q2 2026 results, highlighted by an expanded Nevada Gold Mines joint venture with Newmont. Barrick will vend in Fourmile, Newmont will contribute Mike and Fiberline, creating a nearly 100-million-ounce Nevada complex. Newmont will pay Barrick a $1.95 billion cash top-up within 30 days, resolve all NGM disputes and consent to Barrick’s planned North American gold IPO.
Q2 gold production rose 11% sequentially to 796,000 ounces, beating guidance, while revenues grew 44% year-on-year to $5.29 billion. Net earnings were $1.22 billion (EPS $0.73), adjusted EPS was $0.82 (up 74%), and operating cash flow increased 28% to $1.70 billion. Barrick declared a $0.175 quarterly dividend and repurchased $1.209 billion of shares, lifting Q2 shareholder returns to $1.50 billion (up 242%). 2026 production and cost guidance remain unchanged, but total attributable capital expenditure guidance was reduced to $3.8–$4.2 billion. The North American IPO, including Nevada Gold Mines, Pueblo Viejo, Fourmile and Newmont-contributed assets, is still expected by year-end 2026, with Mark Hill to serve as CEO.
Barrick Mining Corporation (NYSE:B, TSX:ABX) declared a $0.175 per share dividend related to its second quarter 2026 performance. The dividend is payable on September 15, 2026 to shareholders of record at the close of business on August 31, 2026.
Barrick’s dividend policy targets an annual payout of 50% of attributable free cash flow, combining a fixed base quarterly dividend of $0.175 per share with a potential year-end performance top-up, which may vary depending on cash flow strength, capital needs, balance sheet and other factors.
Barrick Mining Corporation (NYSE:B) has appointed Sarah Ball Teslik as Chief Corporate Affairs Officer, Daniel Wilner as Senior Vice President, Corporate Affairs and Capital Markets, and Emily Chieng as Vice President, Investor Relations. The new leadership team will oversee an integrated corporate affairs function, combining communications, investor relations and stakeholder engagement across Barrick’s operations in 17 countries.
Teslik brings over 40 years’ experience in investor stewardship, governance and securities law. Wilner, a long-time advisor to Barrick, will lead the integrated communications and IR team. Chieng, formerly Investor Relations Officer at United States Steel and ex–Goldman Sachs metals and mining analyst, will be based in New York and participate in Barrick’s Q2 2026 results presentation on August 10, 2026.
KKR (NYSE: KKR) has signed definitive agreements for funds it manages to acquire Medicover India, the India hospital operations of Medicover AB (Nasdaq Stockholm: MCOV B). Medicover India, established in 2017, operates 24 multi-specialty hospitals with approximately 4,800 beds across South and West India.
The network offers more than 80 clinical specialties and is supported by over 1,900 doctors, serving millions of patients annually. According to KKR, the investment aligns with its conviction in India’s long-term healthcare development and the objectives of the National Health Policy 2017. Since 2004, KKR has invested more than US$20 billion across the global healthcare ecosystem. The Medicover India transaction remains subject to necessary regulatory approvals, and additional financial details were not disclosed.